Early adopters of GLP-1 drugs have now lost the weight and are beginning to transition off them. How can F&B support the ...

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

People with a higher sense of purpose experience a 46% lower mortality risk and are 33% less likely to develop sleep problems.

When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

It’s hard to turn on the TV these days without seeing ads for drugs like Ozempic, Wegovy, Zepbound or Mounjaro. These ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonist use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use.

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst Lange told an online press conference on Thursday. GLP-1 drugs on the ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

The GLP-1 weight loss space is a particularly thorny area, with a thriving shadow market of not just compounders but research ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...